The Indian group Biocon Biologics, world leader in biosimilar medicines, is taking a major step forward in Morocco. After a commercial start-up, the company plans to build a production site in Casablanca, with an investment of more than 100 million dirhams.
Biocon Biologics, Indian biosimilars giant, is preparing to strengthen its presence in Morocco by establishing a production unit dedicated to innovative drugs. This project, which will mobilize a budget of 100 million dirhams, is part of the group’s strategy aimed at expanding its industrial footprint and meeting the growing demand for treatments against cancer and autoimmune diseases.
A promising industrial project
Less than two years after its establishment in Morocco, Biocon Biologics is moving up a gear. Its Moroccan subsidiary, Biocon Biologics Morocco, until now limited to modest commercial activity with a turnover of 4 million dirhams in 2024, is preparing to make a decisive turning point. The future factory, planned in the Casablanca region, will be dedicated to the manufacture of biosimilar drugs with high added value. These treatments, intended for the Moroccan market, will mainly target serious pathologies such as cancer, diabetes and autoimmune diseases.
Since its inception in 1978 in Bengaluru, India, Biocon Biologics has established itself as a major player in the biosimilars space. These pharmaceutical products, derived from living organisms, have become an essential alternative to traditional treatments. With around twenty products in the final phase of development and investments in research & development exceeding a billion dollars over two decades, the group plays a key role in global therapeutic innovation.
The planned investment in Morocco demonstrates Biocon Biologics’ ambition to expand its product portfolio in the region and contribute to the development of the local pharmaceutical industry. This production site is also part of a broader vision of improving access to care for Moroccan patients.
Although the details of the project have yet to be clarified, the diversification of Biocon Biologics’ activities in the Kingdom is already underway. The subsidiary’s corporate purpose has recently been broadened to include pharmaceutical establishment activity. This development, combined with an initial investment of 5 million dirhams to launch this project, confirms the group’s commitment to the Moroccan market.
The entry into service of the future industrial site should not only boost the subsidiary’s revenues, but also strengthen Morocco’s role as a regional hub for the pharmaceutical industry. The expanded portfolio of locally manufactured products will help meet the needs of Moroccan patients while supporting the kingdom’s efforts to promote innovation and attract investment in the healthcare sector.
